Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: Detection of aplaviroc resistance requires clonal analysis of envelope

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 3, 2009, Pages 1124-1131

  Kitrinos, Kathryn M ^a   Amrine Madsen, Heather ^a   Irlbeck, David M ^a   Michael Word, J ^a   Demarest, James F ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLAVIROC; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENVELOPE GENE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PHYLOGENY; POPULATION RESEARCH; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS ENVELOPE;

ANTI-HIV AGENTS; BENZOATES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EVOLUTION, MOLECULAR; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; PIPERAZINES; PYRIMIDINONES; RITONAVIR; SPIRO COMPOUNDS; TREATMENT FAILURE; TROPISM;

EID: 62949113396     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01057-08     Document Type: Article

References (40)

1. Achaz, G., S. Palmer, M. Kearney, F. Maldarelli, J. W. Mellors, J. M. Coffin, and J. Wakeley. 2004. A robust measure of HIV-1 population turnover within chronically infected individuals. Mol. Biol. Evol. 21:1902-1912.
2. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
3. De Jong, J. J., A. De Ronde, W. Keulen, M. Tersmette, and J. Goudsmit. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66:6777-6780.
4. Demarest, J., S. Shibayama, R. Ferris, C. Vavro, M. St. Clair, and L. Boone. 2004. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity, abstr. WeOr1231. XV Int. AIDS Conf., Bangkok, Thailand, 16 July 2004.
5. Fouchier, R. A., M. Brouwer, S. M. Broersen, and H. Schuitemaker. 1995. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J. Clin. Microbiol. 33:906-911.
6. Fouchier, R. A., M. Groenink, N. A. Kootstra, M. Tersmette, H. G. Huisman, F. Miedema, and H. Schuitemaker. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J. Virol. 66:3183-3187.
7. Grant, R. M., F. M. Hecht, M. Warmerdam, L. Liu, T. Liegler, C. J. Petro-poulos, N. S. Hellmann, M. Chesney, M. P. Busch, and J. O. Kahn. 2002. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288:181-188.
8. Hoffman, N. G., F. Seillier-Moiseiwitsch, J. Ahn, J. M. Walker, and R. Swanstrom. 2002. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J. Virol. 76:3852-3864.
9. Huang, W., S. H. Eshleman, J. Toma, S. Fransen, E. Stawiski, E. E. Paxinos, J. M. Whitcomb, A. M. Young, D. Donnell, F. Mmiro, P. Musoke, L. A. Guay, J. B. Jackson, N. T. Parkin, and C. J. Petropoulos. 2007. Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J. Virol. 81:7885-7893.
10. Hudson, R. R. 2000. A new statistic for detecting genetic differentiation. Genetics 155:2011-2014.
11. Hudson, R. R., D. D. Boos, and N. L. Kaplan. 1992. A statistical test for detecting geographic subdivision. Mol. Biol. Evol. 9:138-151.
12. Irlbeck, D. M., H. A. Madsen, C. LaBranche, K. M. Kitrinos, and J. F. Demarest. 2008. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 22:1425-1431.
13. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2005. Update of the drug resistance mutations in HIV-1: Fall 2005. Top. HIV Med. 13:125-131.
14. Kempf, D. J., M. S. King, B. Bernstein, P. Cernohous, E. Bauer, J. Moseley, K. Gu, A. Hsu, S. Brun, and E. Sun. 2004. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189:51-60.
15. Kitrinos, K., C. LaBranche, M. Stanhope, H. Madsen, and J. Demarest. 2005. Clonal analysis detects pre-existing R5X4-tropic virus in a patient demonstrating population-level tropism shift on 873140 monotherapy. Antivir. Ther. 10:S68.
16. LaBranche, C., K. Kitrinos, R. Howell, C. McDanal, S. Harris, J. Jeffrey, and J. Demarest. 2005. Clonal analysis of in vitro-derived viruses with reduced susceptibility to aplaviroc (873140, APL) shows wide range in IC50 and sequence changes, abstr. 9. First Int. Workshop Target. HIV Entry, Bethesda, MD, 2 to 3 December 2005.
17. LaBranche, C., C. McDanal, and S. Harris. 2005. Analysis ofinvitro-derived viruses exhibiting reduced susceptibility to aplaviroc, abstr. H-1098, p. 278. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., American Society for Microbiology, Washington, DC.
18. Lalezari, J., M. Thompson, P. Kumar, P. Piliero, R. Davey, K. Patterson, A. Shachoy-Clark, K. Adkison, J. Demarest, Y. Lou, M. Berrey, and S. Piscitelli. 2005. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults. AIDS 19:1443-1448.
19. Landovitz, R., G. Faetkenhauer, C. Hoffman, H. Horst, J. M. Strizki, J. Whitcomb, F. Gheyas, D. Knepp, and W. Greaves. 2006. Characterization of susceptibility profiles for the CCR5 antagonist vicriviroc in treatment-naive HIV-infected subjects. Antivir. Ther. 11:S23.
20. MacManus, S., P. J. Yates, R. C. Elston, S. White, N. Richards, and W. Snowden. 2004. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 18:651-655.
21. Maeda, K., H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, Y. Takaoka, S. Shibayama, K. Sagawa, D. Fukushima, J. Moravek, Y. Koyanagi, and H. Mitsuya. 2004. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78:8654-8662.
22. Nei, M. 1987. DNA polymorphism within and between populations, p. 254-286. In Molecular evolutionary genetics. Columbia University Press, New York, NY.
23. Nicholas, K. B., H. B. Nicholas, Jr., and D. W. Deerfield II. 1997. GeneDoc: analysis and visualization of genetic variation. EMBNEW News 4:14.
24. Nichols, W. G., H. M. Steel, T. Bonny, K. Adkison, L. Curtis, J. Millard, K. Kabeya, and N. Clumeck. 2008. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob. Agents Chemother. 52:858-865.
25. Petropoulos, C., W. Huang, J. Toma, S. Fransen, S. Bonhoeffer, and J. Whitcomb. 2004. Resistance to HIV-1 entry inhibitors may occur by multiple molecular mechanisms. Antivir. Ther. 9:S25.
26. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
27. Posada, D., and K. A. Crandall. 1998. MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817-818.
28. Pugach, P., A. J. Marozsan, T. J. Ketas, E. L. Landes, J. P. Moore, and S. E. Kuhmann. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228.
29. Richman, D. D., S. C. Morton, T. Wrin, N. Hellmann, S. Berry, M. F. Shapiro, and S. A. Bozzette. 2004. The prevalence of antiretroviral drug resistance in the United States. AIDS 18:1393-1401.
30. Rozas, J., J. C. Sanchez-DelBarrio, X. Messeguer, and R. Rozas. 2003. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics 19:2496-2497.
31. Strizki, J. M., L. Wojcik, A. J. Marozsan, S. Kuhmann, W. Huang, J. Whitcomb, C. Petropoulos, and J. P Moore. 2005. Properties of in vitro generated HIV-1 variants resistant to the CCR5 antagonist SCH 351125 and SCH 417690. Antivir. Ther. 10:S66.
32. Swofford, D. L. 1998. PAUP*, phylogenetic analysis using parsimony (and other methods) (4.0b10). Sinauer Associates, Sunderland, MA.
33. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The CLUSTAL-X Windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:4876-4882.
34. Trkola, A., S. E. Kuhmann, J. M. Strizki, E. Maxwell, T. Ketas, T. Morgan, P. Pugach, S. Xu, L. Wojcik, J. Tagat, A. Palani, S. Shapiro, J. W. Clader, S. McCombie, G. R. Reyes, B. M. Baroudy, and J. P. Moore. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc. Natl. Acad. Sci. USA 99:395-400.
35. Walmsley, S., B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun, and E. Sun. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:2039-2046.
36. Watson, C., S. Jenkinson, W. Kazmierski, and T. Kenakin. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncom-petitive HIV entry inhibitor. Mol. Pharmacol. 67:1268-1282.
37. Westby, M., M. Lewis, J. Whitcomb, M. Youle, A. L. Pozniak, I. T. James, T. M. Jenkins, M. Perros, and E. van der Ryst. 2006. Emergence ofCXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.
38. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stock-dale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371.
39. Whitcomb, J. M., W. Huang, S. Fransen, K. Limoli, J. Toma, T. Wrin, C. Chappey, L. D. B. Kiss, E. E. Paxinos, and C. J. Petropoulos. 2007. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob. Agents Chemother. 51:566-575.
40. Yeni, P., A. LaMarca, D. Berger, P. Cimoch, A. Lazzarin, P. Salvato, F. M. Smaill, E. Teofilo, S. J. Madison, W. G. Nichols, K. K. Adkison, T. Bonny, J. Millard, D. McCarty, and the EPIC (CCR100136) Study Team. 2009. Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naive patients: results of EPIC study (CCR100136). HIV Med. 10:116-124.